Busulfan – Uses, Dosage, Side Effects, Interaction Busulfan is an orally administered anticancer alkylating agent used in the treatment of chronic myelogenous leukemia, as well as a parenterally administered myeloablative agent used in preparation of hematopoietic cell transplantation (HCT). Busulfan has been linked to transient serum enzyme elevations during therapy, to rare cases of cholestatic hepatitis, instances of nodular regenerative hyperplasia and, when given in high doses, to sinusoidal obstruction syndrome which can be severe and fatal. Busulfan is a synthetic derivative of dimethane-sulfonate with antineoplastic and cytotoxic properties. Although its mechanism of action is not fully understood, busulfan appears to act through the alkylation of DNA. Following systemic absorption of busulfan, carbonium ions are formed, resulting in DNA alkylation and DNA breaks and inhibition of DNA replication and RNA transcription. (NCI04) Busulfan is a methanesulfonate ester that is butane-1,4-diol in which the hydrogens of the hydroxy groups are replaced by methanesulfonyl groups. An alkylating antineoplastic agent, it is used for the treatment of chronic myeloid leukemia (although it has been largely replaced by newer drugs). It is also used as an insect sterilant. It has a role as an insect sterilant, an antineoplastic agent, a teratogenic agent, a carcinogenic agent and an alkylating agent. It is functionally related to a butane-1,4-diol. Mechanism of Action Busulfan is an alkylating agent that contains 2 labile methanesulfonate groups attached to opposite ends of a 4-carbon alkyl chain. Once busulfan is hydrolyzed, the methanesulfonate groups are released and carbonium ions are produced. These carbonium ions alkylate DNA, which results in the interference of DNA replication and RNA transcription, ultimately leading to the disruption of nucleic acid function. Specifically, its mechanism of action through alkylation produces guanine–adenine intrastrand crosslinks. These crosslinks occur through an SN2 reaction guanine N7 nucleophilically attacks the carbon adjacent to the mesylate-leaving group. This kind of damage cannot be repaired by cellular machinery and thus the cell undergoes apoptosis. or The primary molecular action of busulfan is the alkylation of intracellular nucleophiles. Both proteins and nucleic acids are affected. With regard to DNA, busulfan reacts with guanine residues to form a four-carbon di-guanine DNA cross-linkage with the release of methyl sulfonate. The DNA cross-linkage causes misreading of the DNA code and single-strand breakage. The degree of DNA cross-linkage has been shown to be proportional to the dose and cytotoxicity of the compound. Busulfan-induced cross-linkages of DNA to nuclear proteins may also occur and are considered a cytotoxic mechanism. Busulfan has also been reported to esterify phosphate groups of chromosomal DNA, accounting for the fragmentation of chromosomes seen in various cell types after treatment. Chromosomal damage further contributes to the overall cytotoxic effect. Busulfan is an antineoplastic in the class of alkylating agents and is used to treat various forms of cancer. Alkylating agents are so named because of their ability to add alkyl groups to many electronegative groups under conditions present in cells. They stop tumor growth by cross-linking guanine bases in DNA double-helix strands – directly attacking DNA. This makes the strands unable to uncoil and separate. As this is necessary in DNA replication, the cells can no longer divide. In addition, these drugs add methyl or other alkyl groups onto molecules where they do not belong which in turn leads to a miscoding of DNA. Alkylating agents are cell cycle-nonspecific and work by three different mechanisms, all of which achieve the same end result – disruption of DNA function and cell death. Overexpression of MGST2, a glutathione s-transferase, is thought to confer resistance to busulfan. The role of MGST2 in the metabolism of busulfan is unknown however. Indication For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia (FDA has designated busulfan as an orphan drug for this use). It is also used as a component of pretransplant conditioning regimens in patients undergoing bone marrow transplantation for acute myeloid leukemia and nonmalignant diseases. Busulfan is used in pediatrics and adults in combination with cyclophosphamide or fludarabine/clofarabine as a conditioning agent prior to bone marrow transplantation, especially in chronic myelogenous leukemia (CML) and other leukemias, lymphomas, and myeloproliferative disorders. Busulfan can control tumor burden but cannot prevent transformation or correct cytogenic abnormalities. Busulfan Fresenius Kabi followed by cyclophosphamide (BuCy2) is indicated as conditioning treatment prior to conventional hematopoietic progenitor cell transplantation (HPCT) in adult patients when the combination is considered the best available option. Busulfan Fresenius Kabi followed by cyclophosphamide (BuCy4) or melphalan (BuMel) is indicated as conditioning treatment prior to conventional hematopoietic progenitor cell transplantation in pediatric patients. Busilvex followed by cyclophosphamide (BuCy2) is indicated as conditioning treatment prior to conventional hematopoietic progenitor cell transplantation (HPCT) in adult patients when the combination is considered the best available option. Busilvex following fludarabine (FB) is indicated as conditioning treatment prior to hematopoietic progenitor cell transplantation (HPCT) in adult patients who are candidates for a reduced-intensity conditioning (RIC) regimen. Busilvex followed by cyclophosphamide (BuCy4) or melphalan (BuMel) is indicated as conditioning treatment prior to conventional hematopoietic progenitor cell transplantation in pediatric patients. Essential Thrombocythemia (ET) Leukemia Chronic Myelogenous Leukemia (CML) Polycythemia Vera (PV) Use in Cancer Busulfan is approved to treat: Chronic myelogenous leukemia (CML). It is used as palliative treatment. This use is approved for the Myleran brand of busulfan. It is also used with other drugs to prepare patients with CML for a stem cell transplant. This use is approved for the Busulfex brand of busulfan. Busulfan is also being studied in the treatment of other types of cancer. Contraindication a bad infection low amount of magnesium in the blood low amount of potassium in the blood significantly decreased activity of the bone marrow anemia decreased blood platelets low levels of a type of white blood cell called neutrophils hepatic veno-occlusive disease, a type of liver disease a condition where there is formation of fibrous tissue in the lung called pulmonary fibrosis seizures high blood sugar pregnancy a patient who is producing milk and breastfeeding Fanconi’s anemia Dosage Strengths: 2 mg; 6 mg/mL Chronic Myelogenous Leukemia Initial dose: 60 mcg/kg OR 1.8 mg/m2 orally once a day The usual adult dose range for remission induction is 4 to 8 mg/day The dosing presented here is the manufacturer-recommended dosing. The local protocol should be consulted. Since the rate of fall of the leukocyte count is dose related, daily doses exceeding 4 mg per day should be reserved for patients with the most compelling symptoms; the greater the total daily dose, the greater is the possibility of inducing bone marrow aplasia. A decrease in the leukocyte count is not usually seen during the first 10 to 15 days of therapy; the leukocyte count may increase during this period and it should not be interpreted as resistance to the drug, nor should the dose be increased. Since the leukocyte count may continue to fall for more than 1 month after discontinuing the drug, it is important that it be discontinued prior to the total leukocyte count falling into the normal range. When the total leukocyte count has declined to approximately 15,000/mcL, the drug should be withheld. With a constant dose of this drug, the total leukocyte count declines exponentially; a weekly plot of the leukocyte count on semi-logarithmic graph paper aids in predicting the time when therapy should be discontinued. With the recommended dose of this drug, a normal leukocyte count is usually achieved in 12 to 20 weeks. During remission, the patient should be examined at monthly intervals and therapy resumed with the induction dosage when the total leukocyte count reaches approximately 50,000/mcL. When remission is shorter than 3 months, maintenance therapy of 1 to 3 mg orally daily may be advisable to keep the hematological status under control and prevent rapid relapse. For the palliative treatment of chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia Bone Marrow Transplantation 0.8 mg/kg ( ideal body weight or actual body weight, whichever is lower) IV via a central venous catheter as a 2-hour infusion every 6 hours for 4 consecutive days for a total of 16 doses (Days 7, 6, 5, and 4) followed by cyclophosphamide 60 mg/kg IV as a 1-hour infusion on each of 2 days beginning no sooner than 6 hours following the sixteenth dose of busulfan (Days 3 and 2); administer hematopoietic progenitor cells on Day 0 The dosing presented here is the manufacturer-recommended dosing. The local protocol should be consulted. For obese or severely obese patients, base dosing of this drug on adjusted ideal body weight (AIBW). Premedicate with prophylactic anticonvulsant therapy (e.g., phenytoin, levetiracetam, benzodiazepines, or valproic acid) beginning 12 hours prior to high-dose therapy and continuing for 24 hours after the last dose. This drug is associated with a moderate emetic potential (depending on dose and/or administration route). Antiemetics may be necessary to prevent nausea and vomiting. Antiemetics are recommended when used for transplantation. Administer as IV infusion. Do not administer as an IV push or bolus. Pediatric Dose for Chronic Myelogenous Leukemia 60 mcg/kg OR 1.8 mg/m2 orally once a day The dosing presented here is the manufacturer-recommended dosing. The local protocol should be consulted. Since the rate of fall of the leukocyte count is dose related, daily doses exceeding 4 mg per day should be reserved for patients with the most compelling symptoms; the greater the total daily dose, the greater is the possibility of inducing bone marrow aplasia. A decrease in the leukocyte count is not usually seen during the first 10 to 15 days of therapy; the leukocyte count may increase during this period and it should not be interpreted as resistance to the drug, nor should the dose be increased. Since the leukocyte count may continue to fall for more than 1 month after discontinuing the drug, it is important that it be discontinued prior to the total leukocyte count falling into the normal range. When the total leukocyte count has declined to approximately 15,000/mcL, the drug should be withheld. With a constant dose of this drug, the total leukocyte count declines exponentially; a weekly plot of the leukocyte count on semi-logarithmic graph paper aids in predicting the time when therapy should be discontinued. With the recommended dose of this drug, a normal leukocyte count is usually achieved in 12 to 20 weeks. During remission, the patient should be examined at monthly intervals and therapy resumed with the induction dosage when the total leukocyte count reaches approximately 50,000/mcL. When remission is shorter than 3 months, maintenance therapy of 1 to 3 mg orally daily may be advisable to keep the hematological status under control and prevent rapid relapse. Bone Marrow Transplantation Initial Dose: Less than or equal to 12 kg: 1.1 mg/kg (based on actual body weight) Greater than 12 kg: 0.8 mg/kg (based on actual body weight) Doses are administered every 6 hours as 2-hour infusions over 4 days for a total of 16 doses. Therapeutic drug monitoring and dose adjustment following the first dose of busulfan is recommended. Consult the manufacturer’s product information or local protocol for recommended dose adjustments. Administration advice: Infusion pumps should be used to administer the diluted IV injection solution. Set the flow rate of the pump to deliver the entire dose over 2 hours. Prior to and following each infusion, flush the indwelling catheter line with approximately 5 mL of 0.9% sodium chloride injection or 5% dextrose injection. Rapid infusion of the injection has not been tested and is not recommended. Storage requirements: Unopened vials of this drug should be stored under refrigerated conditions between 2C to 8C (36F to 46F). Vials diluted with 0.9% sodium chloride injection or 5% dextrose injection are stable at room temperature (25C) for up to 8 hours but the infusion must be completed within that time. Vials diluted with 0.9% sodium chloride injection are stable at refrigerated conditions (2C to 8C) for up to 12 hours but the infusion must be completed within that time. Store the tablet formulation at 25C (77F); excursions are permitted to 15C to 30C (59 to 86F). Reconstitution/preparation techniques Skin reactions may occur with accidental exposure. Use gloves when preparing this drug. If the reconstituted IV solution contacts the skin or mucosa, wash the skin or mucosa thoroughly with water. Due to incompatibility, do not use any infusion components containing polycarbonate with this drug. Visually inspect parenteral drug products for particulate matter and discoloration prior to administration whenever the solution and container permit. Do not use if particulate matter is seen in the vial. The IV injection must be diluted prior to infusion with either 0.9% sodium chloride injection or 5% dextrose injection. The diluent quantity should be 10 times the volume of busulfan injection, so that the final concentration of busulfan is approximately 0.5 mg per mL. Consult the manufacturer product information for reconstitution details. Do not put the busulfan injection into an IV bag or large-volume syringe that does not contain normal saline or D5W. Always add the busulfan injection to the diluent, not the diluent to the busulfan injection. Mix thoroughly by inverting several times. IV compatibility: The IV formulation of this drug may be reconstituted with 0.9% sodium chloride injection or 5% dextrose injection. Do not infuse this drug concomitantly with another IV solution of unknown compatibility. General: This drug is cytotoxic. Follow applicable special handling and disposal procedures. Monitoring: Monitor the patient for myelosuppression. Side Effects The Most Common nausea diarrhea loss of appetite or weight constipation sores in the mouth and throat dry mouth headache difficulty falling asleep or staying asleep feeling unusually anxious or worried dizziness swelling of the face, arms, hands, feet, ankles or lower legs chest pain joint, muscle or back pain skin rash itching and dry skin darkened skin hair loss black, tarry stools red urine unusual tiredness or weakness difficulty breathing changes in vision vomiting stomach pain seizures More Common easy bruising, unusual bleeding, purple or red spots under your skin; fever, chills, tiredness, sore throat; cough, trouble breathing, chest pain, wheezing; coughing with bloody mucus; pale skin, cold hands and feet; vision problems; persistent cough, congestion, or breathing problems that occur several months or years after using busulfan; a seizure; adrenal gland problems–nausea, vomiting, loss of appetite, weight loss and severe weakness or tired feeling; signs of a heart problem–stomach pain, vomiting, sharp chest pain, trouble breathing; signs of liver problems–weight gain, stomach swelling or tenderness, jaundice (yellowing of the skin or eyes); o signs of an electrolyte imbalance–muscle contractions, muscle weakness, leg cramps, irregular heartbeats, fluttering in your chest, increased thirst or urination, numbness or tingling. Rare red or purple skin rash with blistering and peeling, easy bruising, unusual bleeding, chills, tiredness, sore throat, cough, wheezing, coughing with bloody mucus, pale skin, cold hands and feet, vision problems, persistent cough, congestion, breathing problems that occur several months or years after using the medication, seizure, nausea, vomiting, loss of appetite, weight loss, severe weakness, tired feeling, stomach pain, sharp chest pain, weight gain, stomach swelling or tenderness, yellowing of the skin or eyes (jaundice), muscle contractions, muscle weakness, leg cramps, irregular heartbeats, fluttering in your chest, increased thirst or urination, and numbness or tingling Drug Interaction DRUG INTERACTION Abametapir The serum concentration of Busulfan can be increased when it is combined with Abametapir. Abatacept The metabolism of Busulfan can be increased when combined with Abatacept. Abciximab The risk or severity of bleeding can be increased when Abciximab is combined with Busulfan. Acalabrutinib The metabolism of Busulfan can be decreased when combined with Acalabrutinib. Acenocoumarol The risk or severity of bleeding can be increased when Acenocoumarol is combined with Busulfan. Acetaminophen Acetaminophen may decrease the excretion rate of Busulfan which could result in a higher serum level. Acetazolamide The metabolism of Busulfan can be decreased when combined with Acetazolamide. Acetyldigitoxin Acetyldigitoxin may decrease the cardiotoxic activities of Busulfan. Acetylsalicylic acid The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Busulfan. Adalimumab The metabolism of Busulfan can be increased when combined with Adalimumab. Adenovirus type 7 The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Busulfan. Albendazole The metabolism of Busulfan can be decreased when combined with Albendazole. Aldesleukin The metabolism of Busulfan can be decreased when combined with Aldesleukin. Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Busulfan. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Busulfan. Allogeneic processed The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Busulfan. Allopurinol The risk or severity of adverse effects can be increased when Allopurinol is combined with Busulfan. Alpelisib The metabolism of Busulfan can be increased when combined with Alpelisib. Alteplase The risk or severity of bleeding can be increased when Alteplase is combined with Busulfan. Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Busulfan. Aminoglutethimide The metabolism of Busulfan can be increased when combined with Aminoglutethimide. Amiodarone The metabolism of Busulfan can be decreased when combined with Amiodarone. Amobarbital The metabolism of Busulfan can be increased when combined with Amobarbital. Amprenavir The metabolism of Busulfan can be decreased when combined with Amprenavir. Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Busulfan. Anagrelide The risk or severity of bleeding can be increased when Anagrelide is combined with Busulfan. Anakinra The metabolism of Busulfan can be increased when combined with Anakinra. Anastrozole The risk or severity of cardiotoxicity can be increased when Busulfan is combined with Anastrozole. Ancrod The risk or severity of bleeding can be increased when Ancrod is combined with Busulfan. Anifrolumab The risk or severity of adverse effects can be increased when Busulfan is combined with Anifrolumab. Anistreplase The risk or severity of bleeding can be increased when Anistreplase is combined with Busulfan. immune globulin The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Busulfan. Anthrax vaccine The risk or severity of infection can be increased when Anthrax vaccine is combined with Busulfan. Antilymphocyte The risk or severity of adverse effects can be increased when Busulfan is combined with Antilymphocyte immunoglobulin (horse). Antithrombin Alfa The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Busulfan. Antithrombin III The risk or severity of bleeding can be increased when Antithrombin III human is combined with Busulfan. Antithymocyte The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Busulfan. Apalutamide The metabolism of Busulfan can be increased when combined with Apalutamide. Apixaban The risk or severity of bleeding can be increased when Apixaban is combined with Busulfan. Apremilast The metabolism of Busulfan can be increased when combined with Apremilast. Aprepitant The metabolism of Busulfan can be decreased when combined with Aprepitant. Ardeparin The risk or severity of bleeding can be increased when Ardeparin is combined with Busulfan. Argatroban The risk or severity of bleeding can be increased when Argatroban is combined with Busulfan. Armodafinil The metabolism of Busulfan can be increased when combined with Armodafinil. Arsenic trioxide The risk or severity of adverse effects can be increased when Busulfan is combined with Arsenic trioxide. Articaine The risk or severity of methemoglobinemia can be increased when Busulfan is combined with Articaine. Asciminib The serum concentration of Busulfan can be increased when it is combined with Asciminib. Astemizole The metabolism of Busulfan can be decreased when combined with Astemizole. COVID-19 Vaccine The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Busulfan. Asunaprevir The metabolism of Busulfan can be increased when combined with Asunaprevir. Atazanavir The metabolism of Busulfan can be decreased when combined with Atazanavir. Avacopan The metabolism of Busulfan can be decreased when combined with Avacopan. Avanafil The serum concentration of Avanafil can be increased when it is combined with Busulfan. Azacitidine The risk or severity of adverse effects can be increased when Azacitidine is combined with Busulfan. Azathioprine The risk or severity of adverse effects can be increased when Azathioprine is combined with Busulfan. Azithromycin The metabolism of Busulfan can be decreased when combined with Azithromycin. Bacillus calmette The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Busulfan. Bacillus calmett The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Busulfan. Bacillus calmette- The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Busulfan. Baricitinib The risk or severity of adverse effects can be increased when Busulfan is combined with Baricitinib. Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Busulfan. BCG vaccine The risk or severity of infection can be increased when BCG vaccine is combined with Busulfan. Beclomethasone dipropionate The metabolism of Busulfan can be increased when combined with Beclomethasone dipropionate. Belatacept The risk or severity of adverse effects can be increased when Busulfan is combined with Belatacept. Belimumab The risk or severity of adverse effects can be increased when Busulfan is combined with Belimumab. Belinostat The risk or severity of adverse effects can be increased when Busulfan is combined with Belinostat. Belumosudil The risk or severity of adverse effects can be increased when Busulfan is combined with Belumosudil. Belzutifan The serum concentration of Busulfan can be decreased when it is combined with Belzutifan. Bemiparin The risk or severity of bleeding can be increased when Bemiparin is combined with Busulfan. Bendamustine The risk or severity of adverse effects can be increased when Busulfan is combined with Bendamustine. Bendroflumethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Busulfan. Benzocaine The risk or severity of methemoglobinemia can be increased when Busulfan is combined with Benzocaine. Benzthiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Busulfan. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Busulfan is combined with Benzyl alcohol. Berotralstat The serum concentration of Busulfan can be increased when it is combined with Berotralstat. Betamethasone The metabolism of Busulfan can be increased when combined with Betamethasone. Betamethasone The metabolism of Busulfan can be increased when combined with Betamethasone phosphate. Betrixaban The risk or severity of bleeding can be increased when Betrixaban is combined with Busulfan. Bevacizumab The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Busulfan. Bexarotene The metabolism of Busulfan can be increased when combined with Bexarotene. Bicalutamide The metabolism of Busulfan can be decreased when combined with Bicalutamide. Bifonazole The metabolism of Busulfan can be decreased when combined with Bifonazole. Bimekizumab The metabolism of Busulfan can be increased when combined with Bimekizumab. Bivalirudin The risk or severity of bleeding can be increased when Bivalirudin is combined with Busulfan. Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Busulfan. Blinatumomab The risk or severity of adverse effects can be increased when Busulfan is combined with Blinatumomab. Boceprevir The metabolism of Busulfan can be decreased when combined with Boceprevir. Bordetella pertussis The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Busulfan. Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Busulfan. Bosentan The metabolism of Busulfan can be increased when combined with Bosentan. Bosutinib The metabolism of Busulfan can be decreased when combined with Bosutinib. Brentuximab vedotin The metabolism of Busulfan can be decreased when combined with Brentuximab vedotin. Brodalumab The risk or severity of adverse effects can be increased when Busulfan is combined with Brodalumab. Budesonide The metabolism of Busulfan can be increased when combined with Budesonide. Bupivacaine The risk or severity of methemoglobinemia can be increased when Busulfan is combined with Bupivacaine. Buprenorphine The metabolism of Busulfan can be decreased when combined with Buprenorphine. Butacaine The risk or severity of methemoglobinemia can be increased when Busulfan is combined with Butacaine. Butalbital The metabolism of Busulfan can be increased when combined with Butalbital. Butamben The risk or severity of methemoglobinemia can be increased when Busulfan is combined with Butamben. Cabazitaxel The risk or severity of adverse effects can be increased when Busulfan is combined with Cabazitaxel. You Might Also Read Ketoprofen; Uses, Dosage, Side Effects, Interactions Calcitriol The metabolism of Busulfan can be increased when combined with Calcitriol. Canakinumab The metabolism of Busulfan can be increased when combined with Canakinumab. Candicidin The metabolism of Busulfan can be decreased when combined with Candicidin. Cangrelor The risk or severity of bleeding can be increased when Cangrelor is combined with Busulfan. Cannabidiol The metabolism of Busulfan can be decreased when combined with Cannabidiol. Capecitabine The risk or severity of adverse effects can be increased when Busulfan is combined with Capecitabine. Caplacizumab The risk or severity of bleeding can be increased when Caplacizumab is combined with Busulfan. Capsaicin The risk or severity of methemoglobinemia can be increased when Busulfan is combined with Capsaicin. Carbamazepine The metabolism of Busulfan can be increased when combined with Carbamazepine. Carboplatin The risk or severity of adverse effects can be increased when Carboplatin is combined with Busulfan. Carfilzomib The risk or severity of adverse effects can be increased when Busulfan is combined with Carfilzomib. Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Busulfan. Cefradine The metabolism of Busulfan can be increased when combined with Cefradine. Cenobamate The serum concentration of Busulfan can be decreased when it is combined with Cenobamate. Cephalexin The metabolism of Busulfan can be decreased when combined with Cephalexin. Ceritinib The metabolism of Busulfan can be decreased when combined with Ceritinib. Cerivastatin The metabolism of Busulfan can be increased when combined with Cerivastatin. Certolizumab pegol The metabolism of Busulfan can be increased when combined with Certolizumab pegol. Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Busulfan. Chloramphenicol The metabolism of Busulfan can be decreased when combined with Chloramphenicol. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Busulfan is combined with Chloroprocaine. Chlorothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Busulfan. Chlorpromazine The metabolism of Busulfan can be increased when combined with Chlorpromazine. Ciclesonide The risk or severity of adverse effects can be increased when Busulfan is combined with Ciclesonide. Cilostazol The risk or severity of bleeding can be increased when Cilostazol is combined with Busulfan. Cimetidine The metabolism of Busulfan can be decreased when combined with Cimetidine. Cinchocaine The risk or severity of methemoglobinemia can be increased when Busulfan is combined with Cinchocaine. Ciprofloxacin The metabolism of Busulfan can be decreased when combined with Ciprofloxacin. Cisapride The metabolism of Busulfan can be decreased when combined with Cisapride. Cisplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Busulfan. Citalopram The metabolism of Busulfan can be decreased when combined with Citalopram. Cladribine The risk or severity of adverse effects can be increased when Cladribine is combined with Busulfan. Clarithromycin The metabolism of Busulfan can be decreased when combined with Clarithromycin. Clevidipine The metabolism of Busulfan can be increased when combined with Clevidipine. Clobazam The metabolism of Busulfan can be increased when combined with Clobazam. Clobetasol propionate The metabolism of Busulfan can be increased when combined with Clobetasol propionate. Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Busulfan. Clofazimine The metabolism of Busulfan can be decreased when combined with Clofazimine. Clofibrate The metabolism of Busulfan can be increased when combined with Clofibrate. Clopidogrel The risk or severity of bleeding can be increased when Clopidogrel is combined with Busulfan. Clostridium tetani The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Busulfan. Clozapine The risk or severity of neutropenia can be increased when Busulfan is combined with Clozapine. Cobicistat The metabolism of Busulfan can be decreased when combined with Cobicistat. Cobimetinib The metabolism of Busulfan can be decreased when combined with Cobimetinib. Cocaine The risk or severity of methemoglobinemia can be increased when Busulfan is combined with Cocaine. Conivaptan The metabolism of Busulfan can be decreased when combined with Conivaptan. Corticotropin The metabolism of Busulfan can be increased when combined with Corticotropin. Cortisone acetate The metabolism of Busulfan can be increased when combined with Cortisone acetate. Corynebacterium ) The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Busulfan. Crizotinib The metabolism of Busulfan can be decreased when combined with Crizotinib. Curcumin The metabolism of Busulfan can be decreased when combined with Curcumin. Cyanocobalamin The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Busulfan. Cyclopenthiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Busulfan. Cyclophosphamide The metabolism of Busulfan can be increased when combined with Cyclophosphamide. Cyclosporine Busulfan may increase the immunosuppressive activities of Cyclosporine. Cyclothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Busulfan. Cyproterone acetate The metabolism of Busulfan can be decreased when combined with Cyproterone acetate. Cytarabine The risk or severity of adverse effects can be increased when Cytarabine is combined with Busulfan. Dabigatran The risk or severity of bleeding can be increased when Dabigatran is combined with Busulfan. Dabigatran etexilate The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Busulfan. Dabrafenib The serum concentration of Busulfan can be decreased when it is combined with Dabrafenib. Dacarbazine The risk or severity of adverse effects can be increased when Dacarbazine is combined with Busulfan. Dacomitinib The metabolism of Busulfan can be decreased when combined with Dacomitinib. Dactinomycin The risk or severity of adverse effects can be increased when Dactinomycin is combined with Busulfan. Dalfopristin The metabolism of Busulfan can be decreased when combined with Dalfopristin. Dalteparin The risk or severity of bleeding can be increased when Dalteparin is combined with Busulfan. Danaparoid The risk or severity of bleeding can be increased when Danaparoid is combined with Busulfan. Danazol The metabolism of Busulfan can be decreased when combined with Danazol. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Busulfan. Darunavir The serum concentration of Busulfan can be increased when it is combined with Darunavir. Dasatinib The metabolism of Busulfan can be decreased when combined with Dasatinib. Daunorubicin The metabolism of Busulfan can be decreased when combined with Daunorubicin. Decitabine The risk or severity of adverse effects can be increased when Busulfan is combined with Decitabine. Deferasirox The metabolism of Busulfan can be increased when combined with Deferasirox. Defibrotide The risk or severity of bleeding can be increased when Defibrotide is combined with Busulfan. Deflazacort The metabolism of Busulfan can be increased when combined with Deflazacort. Delavirdine The metabolism of Busulfan can be decreased when combined with Delavirdine. Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Busulfan. Desipramine The metabolism of Busulfan can be decreased when combined with Desipramine. Desirudin The risk or severity of bleeding can be increased when Desirudin is combined with Busulfan. Deslanoside Deslanoside may decrease the cardiotoxic activities of Busulfan. Desoximetasone The risk or severity of adverse effects can be increased when Desoximetasone is combined with Busulfan. Desvenlafaxine The metabolism of Busulfan can be decreased when combined with Desvenlafaxine. Deucravacitinib The risk or severity of adverse effects can be increased when Busulfan is combined with Deucravacitinib. Dexamethasone The metabolism of Busulfan can be increased when combined with Dexamethasone. Dexamethasone acetate The metabolism of Busulfan can be increased when combined with Dexamethasone acetate. Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Busulfan. Dextran The risk or severity of bleeding can be increased when Dextran is combined with Busulfan. Dextropropoxyphene The metabolism of Busulfan can be decreased when combined with Dextropropoxyphene. Dicloxacillin The metabolism of Busulfan can be increased when combined with Dicloxacillin. Dicoumarol The risk or severity of bleeding can be increased when Dicoumarol is combined with Busulfan. Diethylstilbestrol The metabolism of Busulfan can be decreased when combined with Diethylstilbestrol. Difluocortolone The metabolism of Busulfan can be increased when combined with Difluocortolone. Digitoxin Digitoxin may decrease the cardiotoxic activities of Busulfan. Digoxin Digoxin may decrease the cardiotoxic activities of Busulfan. Dihydroergocornine The metabolism of Busulfan can be decreased when combined with Dihydroergocornine. Dihydroergocristine The metabolism of Busulfan can be decreased when combined with Dihydroergocristine. Dihydroergotamine The metabolism of Busulfan can be decreased when combined with Dihydroergotamine. Diltiazem The metabolism of Busulfan can be decreased when combined with Diltiazem. Dimethyl fumarate The risk or severity of adverse effects can be increased when Busulfan is combined with Dimethyl fumarate. Dinutuximab The risk or severity of adverse effects can be increased when Busulfan is combined with Dinutuximab. Diosmin The metabolism of Busulfan can be decreased when combined with Diosmin. Diphenhydramine The risk or severity of methemoglobinemia can be increased when Busulfan is combined with Diphenhydramine. Dipyridamole The risk or severity of bleeding can be increased when Dipyridamole is combined with Busulfan. Diroximel fumarate The risk or severity of adverse effects can be increased when Busulfan is combined with Diroximel fumarate. Docetaxel The metabolism of Busulfan can be decreased when combined with Docetaxel. Doxazosin The metabolism of Busulfan can be decreased when combined with Doxazosin. Doxorubicin The metabolism of Busulfan can be decreased when combined with Doxorubicin. Dronedarone The serum concentration of Busulfan can be increased when it is combined with Dronedarone. Drospirenone The metabolism of Busulfan can be decreased when combined with Drospirenone. Drotrecogin alfa The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Busulfan. Duvelisib The metabolism of Busulfan can be decreased when combined with Duvelisib. Dyclonine The risk or severity of methemoglobinemia can be increased when Busulfan is combined with Dyclonine. Ebastine The metabolism of Busulfan can be decreased when combined with Ebastine. Ebola Zaire vaccine The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Busulfan. Echinacea The metabolism of Busulfan can be increased when combined with Echinacea. Eculizumab The risk or severity of adverse effects can be increased when Busulfan is combined with Eculizumab. Edetic acid The risk or severity of bleeding can be increased when Edetic acid is combined with Busulfan. Edoxaban The risk or severity of bleeding can be increased when Edoxaban is combined with Busulfan. Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Busulfan. Efavirenz The metabolism of Busulfan can be decreased when combined with Efavirenz. Elexacaftor The metabolism of Busulfan can be decreased when combined with Elexacaftor. Elvitegravir The metabolism of Busulfan can be decreased when combined with Elvitegravir. Emapalumab The metabolism of Busulfan can be increased when combined with Emapalumab. Enasidenib The metabolism of Busulfan can be increased when combined with Enasidenib. Enoxaparin The risk or severity of bleeding can be increased when Enoxaparin is combined with Busulfan. Enzalutamide The serum concentration of Busulfan can be decreased when it is combined with Enzalutamide. Epinephrine The metabolism of Busulfan can be decreased when combined with Epinephrine. Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Busulfan. Epoprostenol The risk or severity of bleeding can be increased when Epoprostenol is combined with Busulfan. Eptifibatide The risk or severity of bleeding can be increased when Eptifibatide is combined with Busulfan. Ergotamine The metabolism of Busulfan can be decreased when combined with Ergotamine. Eribulin The risk or severity of adverse effects can be increased when Busulfan is combined with Eribulin. Erlotinib The metabolism of Busulfan can be decreased when combined with Erlotinib. Erythromycin The metabolism of Busulfan can be decreased when combined with Erythromycin. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Busulfan. Esketamine The metabolism of Busulfan can be increased when combined with Esketamine. Eslicarbazepine The metabolism of Busulfan can be increased when combined with Eslicarbazepine. Eslicarbazepine The metabolism of Busulfan can be increased when combined with Eslicarbazepine acetate. Estetrol The metabolism of Busulfan can be decreased when combined with Estetrol. Estradiol acetate The metabolism of Busulfan can be increased when combined with Estradiol acetate. Estradiol benzoate The metabolism of Busulfan can be increased when combined with Estradiol benzoate. Estradiol cypionate The metabolism of Busulfan can be increased when combined with Estradiol cypionate. Estradiol dienanthate The metabolism of Busulfan can be increased when combined with Estradiol dienanthate. Estradiol valerate The metabolism of Busulfan can be increased when combined with Estradiol valerate. Estramustine The risk or severity of adverse effects can be increased when Busulfan is combined with Estramustine. Etanercept The metabolism of Busulfan can be increased when combined with Etanercept. Ethambutol The metabolism of Busulfan can be decreased when combined with Ethambutol. Ethanol The metabolism of Busulfan can be increased when combined with Ethanol. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Busulfan is combined with Ethyl chloride. Etidocaine The risk or severity of methemoglobinemia can be increased when Busulfan is combined with Etidocaine. Etoposide The risk or severity of adverse effects can be increased when Etoposide is combined with Busulfan. Etoricoxib The metabolism of Busulfan can be decreased when combined with Etoricoxib. Etravirine The metabolism of Busulfan can be increased when combined with Etravirine. Everolimus The risk or severity of adverse effects can be increased when Busulfan is combined with Everolimus. Famtozinameran The therapeutic efficacy of Famtozinameran can be decreased when used in combination with Busulfan. Felbamate The metabolism of Busulfan can be increased when combined with Felbamate. Fenofibrate The metabolism of Busulfan can be decreased when combined with Fenofibrate. Fexinidazole The metabolism of Busulfan can be decreased when combined with Fexinidazole. Filgotinib The risk or severity of adverse effects can be increased when Busulfan is combined with Filgotinib. Fingolimod Busulfan may increase the immunosuppressive activities of Fingolimod. Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Busulfan. Flucloxacillin The metabolism of Busulfan can be increased when combined with Flucloxacillin. Fluconazole The metabolism of Busulfan can be decreased when combined with Fluconazole. Flucytosine The risk or severity of adverse effects can be increased when Busulfan is combined with Flucytosine. Fludarabine The risk or severity of adverse effects can be increased when Busulfan is combined with Fludarabine. Fludrocortisone The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Busulfan. Fluindione The risk or severity of bleeding can be increased when Fluindione is combined with Busulfan. Flunisolide The metabolism of Busulfan can be increased when combined with Flunisolide. Fluocinolone The metabolism of Busulfan can be increased when combined with Fluocinolone acetonide. Fluocinonide The metabolism of Busulfan can be increased when combined with Fluocinonide. Fluocortolone The metabolism of Busulfan can be increased when combined with Fluocortolone. Fluorometholone The risk or severity of adverse effects can be increased when Fluorometholone is combined with Busulfan. Fluorouracil The risk or severity of adverse effects can be increased when Fluorouracil is combined with Busulfan. Fluoxetine The metabolism of Busulfan can be decreased when combined with Fluoxetine. Flupentixol The risk or severity of myelosuppression can be increased when Flupentixol is combined with Busulfan. Fluprednisolone The risk or severity of adverse effects can be increased when Busulfan is combined with Fluprednisolone. Fluticasone The metabolism of Busulfan can be increased when combined with Fluticasone. Fluticasone furoate The metabolism of Busulfan can be increased when combined with Fluticasone furoate. Fluticasone propionate The metabolism of Busulfan can be decreased when combined with Fluticasone propionate. Fluvoxamine The metabolism of Busulfan can be decreased when combined with Fluvoxamine. Fondaparinux The risk or severity of bleeding can be increased when Fondaparinux is combined with Busulfan. Formestane The metabolism of Busulfan can be increased when combined with Formestane. Fosamprenavir The metabolism of Busulfan can be decreased when combined with Fosamprenavir. Fosaprepitant The metabolism of Busulfan can be increased when combined with Fosaprepitant. Fosnetupitant The metabolism of Busulfan can be decreased when combined with Fosnetupitant. Fosphenytoin The serum concentration of Busulfan can be decreased when it is combined with Fosphenytoin. Fostamatinib The metabolism of Busulfan can be decreased when combined with Fostamatinib. Fusidic acid The metabolism of Busulfan can be decreased when combined with Fusidic acid. Gallium nitrate The risk or severity of adverse effects can be increased when Busulfan is combined with Gallium nitrate. Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Busulfan. Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Busulfan. Gilteritinib The metabolism of Busulfan can be decreased when combined with Gilteritinib. Ginkgo biloba The metabolism of Busulfan can be decreased when combined with Ginkgo biloba. Glatiramer The risk or severity of adverse effects can be increased when Busulfan is combined with Glatiramer. Glecaprevir The metabolism of Busulfan can be decreased when combined with Glecaprevir. Glyburide The metabolism of Busulfan can be decreased when combined with Glyburide. Glycerol phenyl The metabolism of Busulfan can be increased when combined with Glycerol phenylbutyrate. Golimumab The metabolism of Busulfan can be increased when combined with Golimumab. You Might Also Read Melatonin - Uses, Indications, Dosage, Interactions Hydralazine The metabolism of Busulfan can be decreased when combined with Hydralazine. Hydrochlorothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Busulfan. Hydrocortamate The metabolism of Busulfan can be increased when combined with Hydrocortamate. Hydrocortisone The metabolism of Busulfan can be increased when combined with Hydrocortisone. Hydrocortisone acetate The metabolism of Busulfan can be increased when combined with Hydrocortisone acetate. Hydrocortisone butyrate The metabolism of Busulfan can be increased when combined with Hydrocortisone butyrate. Hydrocortisone succinate The metabolism of Busulfan can be increased when combined with Hydrocortisone succinate. Hydroflumethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Busulfan. Hydroxychloroquine The risk or severity of adverse effects can be increased when Busulfan is combined with Hydroxychloroquine. Hydroxyurea The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Busulfan. Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Busulfan. Ibrutinib The risk or severity of adverse effects can be increased when Busulfan is combined with Ibrutinib. Icosapent ethyl The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Busulfan. Idarubicin The risk or severity of adverse effects can be increased when Busulfan is combined with Idarubicin. Idelalisib The risk or severity of adverse effects can be increased when Busulfan is combined with Idelalisib. Ifosfamide The risk or severity of hemorrhagic cystitis can be increased when Busulfan is combined with Ifosfamide. Iloprost The risk or severity of bleeding can be increased when Iloprost is combined with Busulfan. Imatinib The serum concentration of Busulfan can be increased when it is combined with Imatinib. Indinavir The metabolism of Busulfan can be decreased when combined with Indinavir. Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Busulfan. Inebilizumab The risk or severity of infection can be increased when Busulfan is combined with Inebilizumab. Infigratinib The metabolism of Busulfan can be decreased when combined with Infigratinib. Infliximab The metabolism of Busulfan can be increased when combined with Infliximab. Irbesartan The metabolism of Busulfan can be decreased when combined with Irbesartan. Irinotecan The risk or severity of adverse effects can be increased when Irinotecan is combined with Busulfan. Isavuconazole The metabolism of Busulfan can be increased when combined with Isavuconazole. Isavuconazonium The metabolism of Busulfan can be increased when combined with Isavuconazonium. Isoniazid The metabolism of Busulfan can be decreased when combined with Isoniazid. Isradipine The metabolism of Busulfan can be decreased when combined with Isradipine. Itraconazole The metabolism of Busulfan can be decreased when combined with Itraconazole. Ivacaftor The metabolism of Busulfan can be decreased when combined with Ivacaftor. Ivosidenib The metabolism of Busulfan can be increased when combined with Ivosidenib. Ixabepilone The risk or severity of adverse effects can be increased when Busulfan is combined with Ixabepilone. Ixekizumab The risk or severity of adverse effects can be increased when Busulfan is combined with Ixekizumab. COVID-19 Vaccine The therapeutic efficacy of Janssen COVID-19 Vaccine can be decreased when used in combination with Busulfan. Japanese encephalitis The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Busulfan. Ketazolam The metabolism of Busulfan can be decreased when combined with Ketazolam. Ketoconazole The metabolism of Busulfan can be decreased when combined with Ketoconazole. Lacosamide The metabolism of Busulfan can be decreased when combined with Lacosamide. Lanreotide The metabolism of Busulfan can be decreased when combined with Lanreotide. Lapatinib The metabolism of Busulfan can be decreased when combined with Lapatinib. Lefamulin The serum concentration of Busulfan can be increased when it is combined with Lefamulin. Leflunomide The risk or severity of adverse effects can be increased when Busulfan is combined with Leflunomide. Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Busulfan. Lepirudin The risk or severity of bleeding can be increased when Lepirudin is combined with Busulfan. Lesinurad The metabolism of Busulfan can be increased when combined with Lesinurad. Letermovir The metabolism of Busulfan can be decreased when combined with Letermovir. Levobupivacaine The risk or severity of methemoglobinemia can be increased when Busulfan is combined with Levobupivacaine. Levoketoconazole The metabolism of Busulfan can be decreased when combined with Levoketoconazole. Lidocaine The risk or severity of methemoglobinemia can be increased when Busulfan is combined with Lidocaine. Linagliptin The metabolism of Busulfan can be decreased when combined with Linagliptin. Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Busulfan. Lipegfilgrastim Busulfan may increase the myelosuppressive activities of Lipegfilgrastim. Lomitapide The metabolism of Busulfan can be decreased when combined with Lomitapide. Lomustine The risk or severity of adverse effects can be increased when Busulfan is combined with Lomustine. Lonafarnib The metabolism of Busulfan can be decreased when combined with Lonafarnib. Lopinavir The serum concentration of Busulfan can be increased when it is combined with Lopinavir. Lorlatinib The metabolism of Busulfan can be increased when combined with Lorlatinib. Losartan The metabolism of Busulfan can be decreased when combined with Losartan. Lovastatin The metabolism of Busulfan can be decreased when combined with Lovastatin. Lumacaftor The metabolism of Busulfan can be increased when combined with Lumacaftor. Magnesium The serum concentration of Magnesium can be decreased when it is combined with Busulfan. Manidipine The metabolism of Busulfan can be decreased when combined with Manidipine. Mavacamten The serum concentration of Busulfan can be decreased when it is combined with Mavacamten. Measles virus The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Busulfan. Mechlorethamine The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Busulfan. Medroxyprogesterone The metabolism of Busulfan can be increased when combined with Medroxyprogesterone acetate. Meloxicam The risk or severity of methemoglobinemia can be increased when Busulfan is combined with Meloxicam. Melphalan The risk or severity of adverse effects can be increased when Busulfan is combined with Melphalan. Mepolizumab The risk or severity of adverse effects can be increased when Busulfan is combined with Mepolizumab. Meprednisone The metabolism of Busulfan can be increased when combined with Meprednisone. Mercaptopurine The risk or severity of adverse effects can be increased when Busulfan is combined with Mercaptopurine. Metamizole The risk or severity of myelosuppression can be increased when Metamizole is combined with Busulfan. Methadone The metabolism of Busulfan can be decreased when combined with Methadone. Methimazole The metabolism of Busulfan can be decreased when combined with Methimazole. Methotrexate The risk or severity of adverse effects can be increased when Methotrexate is combined with Busulfan. Methoxy polyethylene The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Busulfan. Methylene blue The metabolism of Busulfan can be decreased when combined with Methylene blue. Methylergometrine The metabolism of Busulfan can be decreased when combined with Methylergometrine. Methylphenobarbital The metabolism of Busulfan can be increased when combined with Methylphenobarbital. Methylprednisolone The metabolism of Busulfan can be increased when combined with Methylprednisolone. Methylprednisone The metabolism of Busulfan can be decreased when combined with Methylprednisone. Methysergide The metabolism of Busulfan can be decreased when combined with Methysergide. Metreleptin The metabolism of Busulfan can be increased when combined with Metreleptin. Metronidazole The serum concentration of Busulfan can be increased when it is combined with Metronidazole. Metyrapone The metabolism of Busulfan can be increased when combined with Metyrapone. Miconazole The metabolism of Busulfan can be decreased when combined with Miconazole. Midazolam The metabolism of Busulfan can be decreased when combined with Midazolam. Midostaurin The metabolism of Busulfan can be decreased when combined with Midostaurin. Mifepristone The metabolism of Busulfan can be increased when combined with Mifepristone. Milnacipran The metabolism of Busulfan can be decreased when combined with Milnacipran. Miocamycin The metabolism of Busulfan can be decreased when combined with Miocamycin. Mirtazapine The metabolism of Busulfan can be decreased when combined with Mirtazapine. Mitapivat The metabolism of Busulfan can be increased when combined with Mitapivat. Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Busulfan. Mitotane The metabolism of Busulfan can be increased when combined with Mitotane. Mitoxantrone The risk or severity of adverse effects can be increased when Busulfan is combined with Mitoxantrone. Mobocertinib The serum concentration of Busulfan can be decreased when it is combined with Mobocertinib. Modafinil The metabolism of Busulfan can be increased when combined with Modafinil. Moderna COVID-19 Vaccine The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Busulfan. Modified vaccinia ankara The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Busulfan. Mometasone furoate The metabolism of Busulfan can be increased when combined with Mometasone furoate. Monomethyl fumarate The risk or severity of adverse effects can be increased when Busulfan is combined with Monomethyl fumarate. Mosunetuzumab The metabolism of Busulfan can be decreased when combined with Mosunetuzumab. Mumps virus strain The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Busulfan. Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Busulfan. Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Busulfan. Mycophenolic acid The risk or severity of adverse effects can be increased when Busulfan is combined with Mycophenolic acid. Nadroparin The risk or severity of bleeding can be increased when Nadroparin is combined with Busulfan. Nafcillin The metabolism of Busulfan can be increased when combined with Nafcillin. Naloxone The metabolism of Busulfan can be decreased when combined with Naloxone. Natalizumab The risk or severity of adverse effects can be increased when Busulfan is combined with Natalizumab. Nefazodone The metabolism of Busulfan can be decreased when combined with Nefazodone. Nelarabine The risk or severity of adverse effects can be increased when Busulfan is combined with Nelarabine. Nelfinavir The metabolism of Busulfan can be decreased when combined with Nelfinavir. Netupitant The metabolism of Busulfan can be decreased when combined with Netupitant. Niacin The metabolism of Busulfan can be decreased when combined with Niacin. Nicardipine The metabolism of Busulfan can be decreased when combined with Nicardipine. Nilotinib The metabolism of Busulfan can be decreased when combined with Nilotinib. Nilvadipine The metabolism of Busulfan can be decreased when combined with Nilvadipine. Nimesulide The risk or severity of bleeding can be increased when Nimesulide is combined with Busulfan. Nintedanib The metabolism of Busulfan can be decreased when combined with Nintedanib. Norethisterone The metabolism of Busulfan can be decreased when combined with Norethisterone. Norgestimate The metabolism of Busulfan can be increased when combined with Norgestimate. Noscapine The metabolism of Busulfan can be decreased when combined with Noscapine. Nuvaxovid The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Busulfan. Obinutuzumab The risk or severity of adverse effects can be increased when Busulfan is combined with Obinutuzumab. Ocrelizumab Ocrelizumab may increase the immunosuppressive activities of Busulfan. Octreotide The serum concentration of Busulfan can be increased when it is combined with Octreotide. Ofatumumab The risk or severity of adverse effects can be increased when Busulfan is combined with Ofatumumab. Olaparib The metabolism of Busulfan can be decreased when combined with Olaparib. Omeprazole The metabolism of Busulfan can be increased when combined with Omeprazole. Oritavancin The metabolism of Busulfan can be increased when combined with Oritavancin. Orphenadrine The metabolism of Busulfan can be decreased when combined with Orphenadrine. Osilodrostat The metabolism of Busulfan can be decreased when combined with Osilodrostat. Osimertinib The metabolism of Busulfan can be decreased when combined with Osimertinib. Ouabain Ouabain may decrease the cardiotoxic activities of Busulfan. Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Busulfan. Oxcarbazepine The metabolism of Busulfan can be increased when combined with Oxcarbazepine. Oxetacaine The risk or severity of methemoglobinemia can be increased when Busulfan is combined with Oxetacaine. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Busulfan is combined with Oxybuprocaine. Oxybutynin The metabolism of Busulfan can be decreased when combined with Oxybutynin. Ozanimod The risk or severity of adverse effects can be increased when Busulfan is combined with Ozanimod. Paclitaxel The metabolism of Busulfan can be increased when combined with Paclitaxel. Pacritinib The serum concentration of Busulfan can be increased when it is combined with Pacritinib. Palbociclib The metabolism of Busulfan can be decreased when combined with Palbociclib. Palifermin The therapeutic efficacy of Palifermin can be decreased when used in combination with Busulfan. Panobinostat The risk or severity of adverse effects can be increased when Busulfan is combined with Panobinostat. Parnaparin The risk or severity of bleeding can be increased when Parnaparin is combined with Busulfan. Pasireotide The metabolism of Busulfan can be decreased when combined with Pasireotide. Pazopanib The metabolism of Busulfan can be decreased when combined with Pazopanib. Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Busulfan. Pegcetacoplan The risk or severity of adverse effects can be increased when Busulfan is combined with Pegcetacoplan. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Busulfan. Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Busulfan. Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Busulfan. Peginterferon beta-1a The risk or severity of adverse effects can be increased when Busulfan is combined with Peginterferon beta-1a. Pemetrexed The risk or severity of adverse effects can be increased when Pemetrexed is combined with Busulfan. Penicillamine The risk or severity of adverse effects can be increased when Penicillamine is combined with Busulfan. Pentobarbital The metabolism of Busulfan can be increased when combined with Pentobarbital. Pentosan polysulfate The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Busulfan. Pentostatin The risk or severity of adverse effects can be increased when Pentostatin is combined with Busulfan. Pentoxifylline The risk or severity of bleeding can be increased when Pentoxifylline is combined with Busulfan. Perampanel The metabolism of Busulfan can be increased when combined with Perampanel. Pertussis vaccine The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Busulfan. Pertuzumab The risk or severity of cardiotoxicity can be increased when Busulfan is combined with Pertuzumab. Phenindione The risk or severity of bleeding can be increased when Phenindione is combined with Busulfan. Phenobarbital The metabolism of Busulfan can be increased when combined with Phenobarbital. Phenol The risk or severity of methemoglobinemia can be increased when Busulfan is combined with Phenol. Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Busulfan. Phenylbutazone The metabolism of Busulfan can be increased when combined with Phenylbutazone. Phenytoin The serum concentration of Busulfan can be decreased when it is combined with Phenytoin. Pimavanserin The metabolism of Busulfan can be decreased when combined with Pimavanserin. Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Busulfan. Pimozide The metabolism of Busulfan can be decreased when combined with Pimozide. Piperaquine The metabolism of Busulfan can be decreased when combined with Piperaquine. Pirfenidone The risk or severity of adverse effects can be increased when Busulfan is combined with Pirfenidone. Pitolisant The serum concentration of Busulfan can be decreased when it is combined with Pitolisant. Polythiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Busulfan. Pomalidomide The risk or severity of adverse effects can be increased when Busulfan is combined with Pomalidomide. Ponatinib The risk or severity of adverse effects can be increased when Busulfan is combined with Ponatinib. Ponesimod The risk or severity of adverse effects can be increased when Busulfan is combined with Ponesimod. Posaconazole The metabolism of Busulfan can be decreased when combined with Posaconazole. Pralatrexate The risk or severity of adverse effects can be increased when Busulfan is combined with Pralatrexate. Pralsetinib The metabolism of Busulfan can be increased when combined with Pralsetinib. Pramocaine The risk or severity of methemoglobinemia can be increased when Busulfan is combined with Pramocaine. Prasugrel The risk or severity of bleeding can be increased when Prasugrel is combined with Busulfan. Prednisolone The metabolism of Busulfan can be increased when combined with Prednisolone. Prednisolone acetate The metabolism of Busulfan can be increased when combined with Prednisolone acetate. Prednisolone phosphate The metabolism of Busulfan can be increased when combined with Prednisolone phosphate. Prednisone The risk or severity of adverse effects can be increased when Prednisone is combined with Busulfan. Prednisone acetate The metabolism of Busulfan can be increased when combined with Prednisone acetate. Pretomanid The metabolism of Busulfan can be decreased when combined with Pretomanid. Prilocaine The risk or severity of methemoglobinemia can be increased when Busulfan is combined with Prilocaine. Primaquine The metabolism of Busulfan can be decreased when combined with Primaquine. Primidone The metabolism of Busulfan can be increased when combined with Primidone. Probenecid The metabolism of Busulfan can be increased when combined with Probenecid. Procaine The risk or severity of methemoglobinemia can be increased when Busulfan is combined with Procaine. Procarbazine The risk or severity of adverse effects can be increased when Busulfan is combined with Procarbazine. Proparacaine The risk or severity of methemoglobinemia can be increased when Busulfan is combined with Proparacaine. Propofol The metabolism of Busulfan can be decreased when combined with Propofol. Propoxycaine The risk or severity of methemoglobinemia can be increased when Busulfan is combined with Propoxycaine. Propylthiouracil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Busulfan. Protein C The risk or severity of bleeding can be increased when Protein C is combined with Busulfan. Protein S human The risk or severity of bleeding can be increased when Protein S human is combined with Busulfan. Quinidine The metabolism of Busulfan can be decreased when combined with Quinidine. Quinine The metabolism of Busulfan can be increased when combined with Quinine. Quinupristin The metabolism of Busulfan can be decreased when combined with Quinupristin. Rabies immune The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Busulfan. Rabies virus The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Busulfan. Rabies virus The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Busulfan. Raloxifene The metabolism of Busulfan can be decreased when combined with Raloxifene. Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Busulfan. Ranolazine The metabolism of Busulfan can be decreased when combined with Ranolazine. Ravulizumab The risk or severity of adverse effects can be increased when Busulfan is combined with Ravulizumab. Remdesivir The metabolism of Busulfan can be decreased when combined with Remdesivir. Reteplase The risk or severity of bleeding can be increased when Reteplase is combined with Busulfan. Reviparin The risk or severity of bleeding can be increased when Reviparin is combined with Busulfan. Ribociclib The metabolism of Busulfan can be decreased when combined with Ribociclib. Rifabutin The metabolism of Busulfan can be increased when combined with Rifabutin. Rifampicin The metabolism of Busulfan can be increased when combined with Rifampicin. Rifamycin The metabolism of Busulfan can be increased when combined with Rifamycin. Rifapentine The metabolism of Busulfan can be increased when combined with Rifapentine. Rilonacept The metabolism of Busulfan can be increased when combined with Rilonacept. Rilpivirine The metabolism of Busulfan can be decreased when combined with Rilpivirine. Risankizumab The risk or severity of adverse effects can be increased when Busulfan is combined with Risankizumab. Ritonavir The serum concentration of Busulfan can be increased when it is combined with Ritonavir. Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Busulfan. Rivaroxaban The risk or severity of bleeding can be increased when Rivaroxaban is combined with Busulfan. Rofecoxib The metabolism of Busulfan can be increased when combined with Rofecoxib. Roflumilast Roflumilast may increase the immunosuppressive activities of Busulfan. Ropeginterferon The risk or severity of adverse effects can be increased when Busulfan is combined with Ropeginterferon alfa-2b. Ropivacaine The risk or severity of methemoglobinemia can be increased when Busulfan is combined with Ropivacaine. Rosuvastatin The metabolism of Busulfan can be decreased when combined with Rosuvastatin. Rotavirus vaccine The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Busulfan. Roxithromycin The metabolism of Busulfan can be decreased when combined with Roxithromycin. Rubella virus vaccine The risk or severity of infection can be increased when Rubella virus vaccine is combined with Busulfan. Rucaparib The metabolism of Busulfan can be decreased when combined with Rucaparib. Rufinamide The metabolism of Busulfan can be increased when combined with Rufinamide. Ruxolitinib The risk or severity of adverse effects can be increased when Busulfan is combined with Ruxolitinib. Saquinavir The metabolism of Busulfan can be decreased when combined with Saquinavir. Sarilumab The metabolism of Busulfan can be increased when combined with Sarilumab. Satralizumab The serum concentration of Busulfan can be decreased when it is combined with Satralizumab. Secobarbital The metabolism of Busulfan can be increased when combined with Secobarbital. Secukinumab The metabolism of Busulfan can be increased when combined with Secukinumab. Siltuximab The metabolism of Busulfan can be increased when combined with Siltuximab. Simeprevir The metabolism of Busulfan can be decreased when combined with Simeprevir. Siponimod The risk or severity of adverse effects can be increased when Busulfan is combined with Siponimod. Sipuleucel-T The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Busulfan. Sirolimus The risk or severity of adverse effects can be increased when Sirolimus is combined with Busulfan. Sitaxentan The metabolism of Busulfan can be decreased when combined with Sitaxentan. Smallpox (Vaccinia) The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Busulfan. Sodium citrate The risk or severity of bleeding can be increased when Sodium citrate is combined with Busulfan. Somatostatin The metabolism of Busulfan can be decreased when combined with Somatostatin. Somatrogon The metabolism of Busulfan can be increased when combined with Somatrogon. Sorafenib The risk or severity of adverse effects can be increased when Sorafenib is combined with Busulfan. Sotorasib The serum concentration of Busulfan can be decreased when it is combined with Sotorasib. Spesolimab The risk or severity of adverse effects can be increased when Busulfan is combined with Spesolimab. St. John’s Wort The metabolism of Busulfan can be increased when combined with St. John’s Wort. Stiripentol The metabolism of Busulfan can be decreased when combined with Stiripentol. Streptokinase The risk or severity of bleeding can be increased when Streptokinase is combined with Busulfan. Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Busulfan. Sulfamethoxazole The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Busulfan. Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Busulfan. Sulfinpyrazone The metabolism of Busulfan can be increased when combined with Sulfinpyrazone. Sulodexide The risk or severity of bleeding can be increased when Sulodexide is combined with Busulfan. Sunitinib The risk or severity of adverse effects can be increased when Busulfan is combined with Sunitinib. Suvorexant The metabolism of Busulfan can be decreased when combined with Suvorexant. You Might Also Read Benzenecarbinol - Uses, Dosage, Side Effects Tacrolimus Tacrolimus may increase the immunosuppressive activities of Busulfan. Tamoxifen The metabolism of Busulfan can be increased when combined with Tamoxifen. Tasimelteon The metabolism of Busulfan can be decreased when combined with Tasimelteon. Tazemetostat The metabolism of Busulfan can be decreased when combined with Tazemetostat. Tecovirimat The metabolism of Busulfan can be increased when combined with Tecovirimat. Tedizolid phosphate The risk or severity of myelosuppression can be increased when Busulfan is combined with Tedizolid phosphate. Telaprevir The metabolism of Busulfan can be decreased when combined with Telaprevir. Telithromycin The metabolism of Busulfan can be decreased when combined with Telithromycin. Telotristat ethyl The serum concentration of Busulfan can be decreased when it is combined with Telotristat ethyl. Temozolomide The risk or severity of adverse effects can be increased when Temozolomide is combined with Busulfan. Temsirolimus The risk or severity of adverse effects can be increased when Busulfan is combined with Temsirolimus. Tenecteplase The risk or severity of bleeding can be increased when Tenecteplase is combined with Busulfan. Teniposide The metabolism of Busulfan can be decreased when combined with Teniposide. Tenofovir The metabolism of Busulfan can be decreased when combined with Tenofovir alafenamide. Teprotumumab The risk or severity of adverse effects can be increased when Busulfan is combined with Teprotumumab. Terbinafine The metabolism of Busulfan can be increased when combined with Terbinafine. Terfenadine The metabolism of Busulfan can be decreased when combined with Terfenadine. Teriflunomide The risk or severity of adverse effects can be increased when Busulfan is combined with Teriflunomide. Testosterone The metabolism of Busulfan can be increased when combined with Testosterone. Tetracaine The risk or severity of methemoglobinemia can be increased when Busulfan is combined with Tetracaine. Tetracycline The metabolism of Busulfan can be decreased when combined with Tetracycline. Thalidomide The risk or severity of adverse effects can be increased when Busulfan is combined with Thalidomide. Thiamylal The metabolism of Busulfan can be increased when combined with Thiamylal. Thiotepa The risk or severity of adverse effects can be increased when Busulfan is combined with Thiotepa. Ticagrelor The metabolism of Busulfan can be decreased when combined with Ticagrelor. Tick-borne encephalitis The therapeutic efficacy of Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Busulfan. Ticlopidine The risk or severity of bleeding can be increased when Ticlopidine is combined with Busulfan. Tinzaparin The risk or severity of bleeding can be increased when Tinzaparin is combined with Busulfan. Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Busulfan. Tipranavir The metabolism of Busulfan can be decreased when combined with Tipranavir. Tirofiban The risk or severity of bleeding can be increased when Tirofiban is combined with Busulfan. Tixocortol The risk or severity of adverse effects can be increased when Busulfan is combined with Tixocortol. Tocilizumab The metabolism of Busulfan can be increased when combined with Tocilizumab. Tofacitinib Busulfan may increase the immunosuppressive activities of Tofacitinib. Topiramate The metabolism of Busulfan can be increased when combined with Topiramate. Topotecan The risk or severity of adverse effects can be increased when Busulfan is combined with Topotecan. Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Busulfan. Trabectedin The risk or severity of adverse effects can be increased when Busulfan is combined with Trabectedin. Trastuzumab Trastuzumab may increase the neutropenic activities of Busulfan. Trastuzumab emtansine The risk or severity of adverse effects can be increased when Busulfan is combined with Trastuzumab emtansine. Tretinoin The risk or severity of adverse effects can be increased when Tretinoin is combined with Busulfan. Triamcinolone The metabolism of Busulfan can be increased when combined with Triamcinolone. Trichlormethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Busulfan. Triclabendazole The metabolism of Busulfan can be decreased when combined with Triclabendazole. Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Busulfan. Triflusal The risk or severity of bleeding can be increased when Triflusal is combined with Busulfan. Trilostane The risk or severity of adverse effects can be increased when Busulfan is combined with Trilostane. Troglitazone The metabolism of Busulfan can be increased when combined with Troglitazone. Troleandomycin The metabolism of Busulfan can be decreased when combined with Troleandomycin. Tucatinib The metabolism of Tucatinib can be decreased when combined with Busulfan. Typhoid vaccine The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Busulfan. Typhoid Vaccine Live The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Busulfan. Typhoid Vi polysaccharide The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Busulfan. Upadacitinib The risk or severity of adverse effects can be increased when Busulfan is combined with Upadacitinib. Urokinase The risk or severity of bleeding can be increased when Urokinase is combined with Busulfan. Valproic acid The metabolism of Busulfan can be decreased when combined with Valproic acid. Varicella zoster vaccine The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Busulfan. Varicella zoster vaccine The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Busulfan. Vedolizumab The risk or severity of adverse effects can be increased when Busulfan is combined with Vedolizumab. Vemurafenib The metabolism of Busulfan can be increased when combined with Vemurafenib. Venetoclax The metabolism of Busulfan can be decreased when combined with Venetoclax. Verapamil The metabolism of Busulfan can be decreased when combined with Verapamil. Vibrio cholerae The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Busulfan. Vilanterol The risk or severity of adverse effects can be increased when Busulfan is combined with Vilanterol. Viloxazine The metabolism of Busulfan can be decreased when combined with Viloxazine. Vinblastine The metabolism of Busulfan can be increased when combined with Vinblastine. Vincristine The risk or severity of adverse effects can be increased when Vincristine is combined with Busulfan. Vindesine The risk or severity of adverse effects can be increased when Vindesine is combined with Busulfan. Vinorelbine The risk or severity of adverse effects can be increased when Vinorelbine is combined with Busulfan. Vitamin E The metabolism of Busulfan can be increased when combined with Vitamin E. Voclosporin The risk or severity of adverse effects can be increased when Busulfan is combined with Voclosporin. Vorapaxar The metabolism of Busulfan can be decreased when combined with Vorapaxar. Voriconazole The metabolism of Busulfan can be decreased when combined with Voriconazole. Vorinostat The risk or severity of adverse effects can be increased when Busulfan is combined with Vorinostat. Voxelotor The serum concentration of Busulfan can be increased when it is combined with Voxelotor. Warfarin The metabolism of Busulfan can be increased when combined with Warfarin. Ximelagatran The risk or severity of bleeding can be increased when Ximelagatran is combined with Busulfan. Yellow fever vaccine The risk or severity of infection can be increased when Yellow fever vaccine is combined with Busulfan. Zafirlukast The metabolism of Busulfan can be decreased when combined with Zafirlukast. Zidovudine The risk or severity of adverse effects can be increased when Zidovudine is combined with Busulfan. Zimelidine The metabolism of Busulfan can be decreased when combined with Zimelidine. Ziprasidone The metabolism of Busulfan can be decreased when combined with Ziprasidone. Pregnancy and Lactation Pregnancy Busulfan can cause fetal harm when administered to a pregnant woman based on animal data. Busulfan was teratogenic in mice, rats, and rabbits following administration during organogenesis. The solvent, DMA, may also cause fetal harm when administered to a pregnant woman. In rats, DMA doses of approximately 40% of the daily dose of DMA in the busulfan dose on a mg/m2 basis given during organogenesis caused significant developmental anomalies. There are no available human data informing the drug-associated risk. Advise pregnant women of the potential risk to a fetus. The background risk of major birth defects and miscarriage for the indicated populations are unknown. However, the background risk in the U.S. general population of major birth defects is 2-4% and of miscarriage is 15-20% of clinically recognized pregnancies. Lactation It is not known whether Busulfan is present in human milk. Because many drugs are excreted in human milk and because of the potential for tumorigenicity shown for busulfan in human and animal studies, discontinue breastfeeding during treatment with BUSULFEX. How should this medicine be used? Busulfan comes as a tablet to take by mouth once a day. The length of treatment depends on the types of drugs you are taking, how well your body responds to them, and the type of cancer you have. Take busulfan at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take busulfan exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. Your doctor may adjust your dose of busulfan depending on your response to treatment and any side effects that you experience. Talk to your doctor about how you are feeling during your treatment. Do not stop taking busulfan without talking to your doctor. Other uses for this medicine Busulfan tablets are also used in combination with other drugs to destroy the bone marrow and cancer cells in preparation for a bone marrow transplant. This medication may be prescribed for other uses; ask your doctor or pharmacist for more information. What special precautions should I follow? Before taking busulfan, tell your doctor and pharmacist if you are allergic to busulfan, any other medications, or any of the ingredients in busulfan tablets. Ask your pharmacist for a list of the ingredients. tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: acetaminophen (Tylenol); certain chemotherapy medications such as bendamustine (Treanda), carmustine (BiCNU, Gliadel Wafer), cyclophosphamide (Cytoxan), ifosfamide (Ifex), lomustine (CeeNU), melphalan (Alkeran), procarbazine (Mutalane), temozolomide (Temodar), thioguanine; clozapine (Clozaril, FazaClo); cyclosporine (Sandimmune, Gengraf, Neoral); itraconazole (Sporanox); medications for mental illness and nausea; phenytoin (Dilantin); or meperidine (Demerol). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with busulfan, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list. tell your doctor if you have previously received radiation therapy or treatment with other chemotherapy medications or if you have or have ever had seizures or a head injury. Also tell your doctor if you have taken busulfan before, but your cancer did not respond to the medication. you should know that busulfan may interfere with the normal menstrual cycle (period) in women, may stop sperm production in men. However, you should not assume that you cannot get pregnant or that you cannot get someone else pregnant. Women who are pregnant or breast-feeding should tell their doctors before they begin taking this drug. You should not plan to have children while receiving chemotherapy or for a while after treatments. (Talk to your doctor for further details.) Use a reliable method of birth control to prevent pregnancy. If you become pregnant while taking busulfan, call your doctor immediately. Busulfan may harm the fetus. References https://pubchem.ncbi.nlm.nih.gov/compound/Busulfan https://www.webmd.com/drugs/2/drug-14002/busulfan-oral/details/list-contraindications https://medlineplus.gov/druginfo/meds/a682248.html https://en.wikipedia.org/wiki/Busulfan https://go.drugbank.com/drugs/DB01008 https://www.drugs.com/mtm/busulfan-oral-injection.html CAMEO Chemicals https://cameochemicals.noaa.gov/help/reference/terms_and_conditions.htm?d_f=false MYLERAN https://cameochemicals.noaa.gov/chemical/20718 CAMEO Chemical Reactivity Classification https://cameochemicals.noaa.gov/browse/react CAS Common Chemistry LICENSE The data from CAS Common Chemistry is provided under a CC-BY-NC 4.0 license, unless otherwise stated. https://creativecommons.org/licenses/by-nc/4.0/ Busulfan https://commonchemistry.cas.org/detail?cas_rn=55-98-1 ChemIDplus LICENSE https://www.nlm.nih.gov/copyright.html Busulfan [USP:INN:BAN:JAN] https://chem.nlm.nih.gov/chemidplus/sid/0000055981 ChemIDplus Chemical Information Classification https://chem.nlm.nih.gov/chemidplus/ DrugBank https://www.drugbank.ca/legal/terms_of_use Busulfan https://www.drugbank.ca/drugs/DB01008 DTP/NCI. https://www.cancer.gov/policies/copyright-reuse busulfan https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&outputformat=html&searchlist=755916 busulfan https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&outputformat=html&searchlist=750 EPA DSSTox LICENSE https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources Busulfan https://comptox.epa.gov/dashboard/DTXSID3020910 CompTox Chemicals Dashboard Chemical Lists https://comptox.epa.gov/dashboard/chemical-lists/ European Chemicals Agency (ECHA) https://echa.europa.eu/web/guest/legal-notice Busulfan https://echa.europa.eu/substance-information/-/substanceinfo/100.000.228 Busulfan https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/52943 FDA Global Substance Registration System (GSRS) https://www.fda.gov/about-fda/about-website/website-policies#linking BUSULFAN https://gsrs.ncats.nih.gov/ginas/app/beta/substances/G1LN9045DK Hazardous Substances Data Bank (HSDB) BUSULFAN https://pubchem.ncbi.nlm.nih.gov/source/hsdb/7605 Human Metabolome Database (HMDB) http://www.hmdb.ca/citing Busulfan http://www.hmdb.ca/metabolites/HMDB0015143 HMDB0015143_msms_374259 https://hmdb.ca/metabolites/HMDB0015143#spectra ChEBI Busulfan http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:28901 ChEBI Ontology http://www.ebi.ac.uk/chebi/userManualForward.do#ChEBI%20Ontology FDA Pharm Classes https://www.fda.gov/about-fda/about-website/website-policies#linking BUSULFAN https://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm FDA Pharmacological Classification https://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162549.htm LiverTox LICENSE https://www.nlm.nih.gov/copyright.html Busulfan https://www.ncbi.nlm.nih.gov/books/n/livertox/Busulfan/ NCI Thesaurus (NCIt) https://www.cancer.gov/policies/copyright-reuse https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C321 NCI Thesaurus Tree https://ncit.nci.nih.gov ChEMBL http://www.ebi.ac.uk/Information/termsofuse.html https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL820/ ChEMBL Protein Target Tree https://www.ebi.ac.uk/chembl/g/#browse/targets Comparative Toxicogenomics Database (CTD) http://ctdbase.org/about/legal.jsp https://ctdbase.org/detail.go?type=chem&acc=D002066 Drug Gene Interaction database (DGIdb) LICENSE The data used in DGIdb is all open access and where possible made available as raw data dumps in the downloads section. http://www.dgidb.org/downloads https://www.dgidb.org/drugs/BUSULFAN Therapeutic Target Database (TTD) Busulfan http://idrblab.net/ttd/data/drug/details/D07SUG ClinicalTrials.gov https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use https://clinicaltrials.gov/ DailyMed LICENSE https://www.nlm.nih.gov/copyright.html BUSULFAN https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=BUSULFAN Drug Induced Liver Injury Rank (DILIrank) Dataset https://www.fda.gov/about-fda/about-website/website-policies#linking busulfan https://www.fda.gov/science-research/liver-toxicity-knowledge-base-ltkb/drug-induced-liver-injury-rank-dilirank-dataset European Medicines Agency (EMA) LICENSE Information on the European Medicines Agency’s (EMA) website is subject to a disclaimer and copyright and limited reproduction notices. https://www.ema.europa.eu/en/about-us/legal-notice Busulfan Fresenius Kabi (EMEA/H/C/002806) https://www.ema.europa.eu/en/medicines/human/EPAR/busulfan-fresenius-kabi Busilvex (EMEA/H/C/000472) https://www.ema.europa.eu/en/medicines/human/EPAR/busilvex EU Clinical Trials Register https://www.clinicaltrialsregister.eu/ NITE-CMC Busulfan – FY2009 https://www.nite.go.jp/chem/english/ghs/09-mhlw-0218e.html FDA Orange Book https://www.fda.gov/about-fda/about-website/website-policies#linking https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book NORMAN Suspect List Exchange LICENSE Data: CC-BY 4.0; Code (hosted by ECI, LCSB): Artistic-2.0 https://creativecommons.org/licenses/by/4.0/ NORMAN Suspect List Exchange Classification https://www.norman-network.com/nds/SLE/ WHO Anatomical Therapeutic Chemical (ATC) Classification https://www.whocc.no/copyright_disclaimer/ https://www.whocc.no/atc/ ATC Code https://www.whocc.no/atc_ddd_index/ National Drug Code (NDC) Directory https://www.fda.gov/about-fda/about-website/website-policies#linking BUSULFAN https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory SpectraBase Busulfan https://spectrabase.com/spectrum/CbZP13SVqVs Busulfan https://spectrabase.com/spectrum/CCDAGr1UqPy Busulfan https://spectrabase.com/spectrum/BkOgDSGtcRQ 1,4-Butanediol, dimethanesulfonate https://spectrabase.com/spectrum/1sBw9DvbXqy Busulfan https://spectrabase.com/spectrum/CNGSdckIeer International Agency for Research on Cancer (IARC) https://publications.iarc.fr/Terms-Of-Use Busulfan https://monographs.iarc.who.int/list-of-classifications IARC Classification https://www.iarc.fr/ MassBank of North America (MoNA) LICENSE The content of the MoNA database is licensed under CC BY 4.0. https://mona.fiehnlab.ucdavis.edu/documentation/license Busulfan https://mona.fiehnlab.ucdavis.edu/spectra/browse?query=compound.metaData%3Dq%3D%27name%3D%3D%22InChIKey%22%20and%20value%3D%3D%22COVZYZSDYWQREU-UHFFFAOYSA-N%22%27 NCI Cancer Drugs LICENSE https://www.cancer.gov/policies/copyright-reuse Busulfan https://www.cancer.gov/about-cancer/treatment/drugs/busulfan NIPH Clinical Trials Search of Japan https://rctportal.niph.go.jp/en/ NIST Mass Spectrometry Data Center LICENSE https://www.nist.gov/srd/public-law Busulfan http://www.nist.gov/srd/nist1a.cfm NLM RxNorm Terminology https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html busulfan https://rxnav.nlm.nih.gov/id/rxnorm/1828 NMRShiftDB https://pubchem.ncbi.nlm.nih.gov/substance/87692166 Springer Nature https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=14051367-748537338 SpringerMaterials 1,4-Butanediol, dimethanesulfonate https://materials.springer.com/substanceprofile/docs/smsid_jpsjzlmyygrbtqnw Thieme Chemistry LICENSE The Thieme Chemistry contribution within PubChem is provided under a CC-BY-NC-ND 4.0 license, unless otherwise stated. https://creativecommons.org/licenses/by-nc-nd/4.0/ https://pubchem.ncbi.nlm.nih.gov/substance/?source=22163&sourceid=14051367-748537338 Wikidata LICENSE CCZero https://creativecommons.org/publicdomain/zero/1.0/ Busulfan https://www.wikidata.org/wiki/Q348922 Medical Subject Headings (MeSH) https://www.nlm.nih.gov/copyright.html Busulfan https://www.ncbi.nlm.nih.gov/mesh/68002066 MeSH Tree http://www.nlm.nih.gov/mesh/meshhome.html Antineoplastic Agents, Alkylating https://www.ncbi.nlm.nih.gov/mesh/68018906 Immunosuppressive Agents https://www.ncbi.nlm.nih.gov/mesh/68007166 Myeloablative Agonists https://www.ncbi.nlm.nih.gov/mesh/68019653 Alkylating Agents https://www.ncbi.nlm.nih.gov/mesh/68000477 PubChem https://pubchem.ncbi.nlm.nih.gov KEGG LICENSE Academic users may freely use the KEGG website. Non-academic use of KEGG generally requires a commercial license https://www.kegg.jp/kegg/legal.html Therapeutic category of drugs in Japan http://www.genome.jp/kegg-bin/get_htext?br08301.keg USP drug classification http://www.genome.jp/kegg-bin/get_htext?br08302.keg Anatomical Therapeutic Chemical (ATC) classification http://www.genome.jp/kegg-bin/get_htext?br08303.keg Drugs listed in the Japanese Pharmacopoeia http://www.genome.jp/kegg-bin/get_htext?br08311.keg Drug Groups http://www.genome.jp/kegg-bin/get_htext?br08330.keg UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS) GHS Classification Tree http://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html EPA Substance Registry Services LICENSE https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources EPA SRS List Classification https://sor.epa.gov/sor_internet/registry/substreg/LandingPage.do PATENTSCOPE (WIPO) SID 403415860 https://pubchem.ncbi.nlm.nih.gov/substance/403415860 NCBI https://www.ncbi.nlm.nih.gov/projects/linkout , Show More